Management of tricuspid valve regurgitation: Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease.

@article{Antunes2017ManagementOT,
  title={Management of tricuspid valve regurgitation: Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease.},
  author={Manuel de Jesus Antunes and Jos{\'e} Fernando Rodr{\'i}guez-Palomares and Bernard D. Prendergast and Michele De Bonis and Raphael A Rosenhek and Nawwar H K Al-Attar and Fabio Barili and Filip P Casselman and Thierry A. Folliguet and Bernard Iung and Patrizio Lancellotti and Claudio Muneretto and Jean-François Obadia and L. Pierard and Piotr Suwalski and Pepe Zamorano},
  journal={European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery},
  year={2017},
  volume={52 6},
  pages={
          1022-1030
        }
}
Tricuspid regurgitation (TR) is a very frequent manifestation of valvular heart disease. It may be due to the primary involvement of the valve or secondary to pulmonary hypertension or to the left-sided heart valve disease (most commonly rheumatic and involving the mitral valve). The pathophysiology of secondary TR is complex and is intrinsically connected to the anatomy and function of the right ventricle. A systematic multimodality approach to diagnosis and assessment (based not only on the… CONTINUE READING